Fox Run Management L.L.C. acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 8,600 shares of the biopharmaceutical company’s stock, valued at approximately $574,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of AGIO. QS Investors LLC purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $144,000. Russell Investments Group Ltd. lifted its stake in shares of Agios Pharmaceuticals by 163.9% in the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,583 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 3,123 shares during the period. Aperio Group LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $206,000. Finally, Parametrica Management Ltd acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $228,000. 93.16% of the stock is currently owned by institutional investors and hedge funds.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down $0.09 during mid-day trading on Tuesday, reaching $61.96. 329,700 shares of the company’s stock traded hands, compared to its average volume of 529,561. Agios Pharmaceuticals, Inc. has a 52-week low of $39.24 and a 52-week high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same quarter in the prior year, the business earned ($1.63) earnings per share. The firm’s revenue for the quarter was up 26.4% on a year-over-year basis. equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current year.
In related news, CEO David P. Schenkein sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $62.20, for a total value of $373,200.00. Following the transaction, the chief executive officer now directly owns 6,000 shares of the company’s stock, valued at approximately $373,200. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total value of $227,400.00. The disclosure for this sale can be found here. Insiders have sold 178,908 shares of company stock valued at $12,147,719 in the last three months. Insiders own 10.55% of the company’s stock.
A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price target on the stock. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a report on Monday, September 18th. SunTrust Banks, Inc. reissued a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Finally, Janney Montgomery Scott reissued a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, August 1st. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $75.70.
ILLEGAL ACTIVITY WARNING: “Fox Run Management L.L.C. Invests $574,000 in Agios Pharmaceuticals, Inc. (AGIO) Stock” was originally published by Week Herald and is owned by of Week Herald. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://weekherald.com/2017/11/14/8600-shares-in-agios-pharmaceuticals-inc-agio-purchased-by-fox-run-management-l-l-c.html.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.